Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

References

• GBD 2015 Chronic Respiratory Disease CollaboratorsGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA) [homepage] Available from: http://ginasthma.org/Accessed February 1, 2018
   Google Scholar
• BatemanEDHurdSSBarnesPJGlobal strategy for asthma management and prevention: GINA executive summaryEur Respir J200831114317818166595
   PubMed Web of Science ®Google Scholar
• ChungKFWenzelSEBrozekJLInternational ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEur Respir J201443234337324337046
   PubMed Web of Science ®Google Scholar
• LarssonKStällbergBLisspersKPrevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR)Respir Res20181911229347939
   PubMed Web of Science ®Google Scholar
• ChastekBKorrerSNagarSPEconomic burden of illness among patients with severe asthma in a managed care settingJ Manag Care Spec Pharm201622784886127348285
   PubMedGoogle Scholar
• LefebvrePDuhMSLafeuilleMHBurden of systemic gluco-corticoid-related complications in severe asthmaCurr Med Res Opin2017331576527627132
   PubMed Web of Science ®Google Scholar
• KingGGJamesAHarknessLWarkPABPathophysiology of severe asthma: we’ve only just startedRespirology201823326227129316003
   PubMed Web of Science ®Google Scholar
• CanonicaGWSennaGMitchellPDO’ByrnePMPassalacquaGVarricchiGTherapeutic interventions in severe asthmaWorld Allergy Organ J2016914027942351
   PubMed Web of Science ®Google Scholar
• RichardsLBNeerincxAHvan BragtJJMHSterkPJBelEHDMaitland-van der ZeeAHBiomarkers and asthma management: analysis and potential applicationsCurr Opin Allergy Clin Immunol20181829610829389730
   PubMed Web of Science ®Google Scholar
• SvenningsenSNairPAsthma endotypes and an overview of targeted therapy for asthmaFront Med20174158
   PubMed Web of Science ®Google Scholar
• CanonicaGWFerrandoMBaiardiniIAsthma: personalized and precision medicineCurr Opin Allergy Clin Immunol2018181515829189350
   PubMed Web of Science ®Google Scholar
• GodarMBlanchetotCde HaardHLambrechtBNBrusselleGPersonalized medicine with biologics for severe type 2 asthma: current status and future prospectsMAbs2018101344529035619
   PubMed Web of Science ®Google Scholar
• ChungKFTargeting the interleukin pathway in the treatment of asthmaLancet201538699981086109626383000
   PubMed Web of Science ®Google Scholar
• WalshGMProfile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthmaBiologics2013771123326187
   PubMedGoogle Scholar
• EganRWAthwalDBodmerMWEffect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivityArzneimittelforschung199949977979010514907
   PubMed Web of Science ®Google Scholar
• CardetJCIsraelEUpdate on reslizumab for eosinophilic asthmaExpert Opin Biol Ther201515101531153926372797
   PubMed Web of Science ®Google Scholar
• LimHNairPEfficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthmaExp Rev Respir Med201592135142
   PubMed Web of Science ®Google Scholar
• ZhangJKuvelkarRMurgoloNJMapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5Int Immunol199911121935194410590259
   PubMed Web of Science ®Google Scholar
• WalshGMReslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditionsCurr Opin Mol Ther200911332933619479666
   PubMedGoogle Scholar
• EganRWAthwahlDChouCCInhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5Int Arch Allergy Immunol19951071–33213227613159
   PubMed Web of Science ®Google Scholar
• CastroMMathurSHargreaveFRes-5-0010 Study GroupReslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled studyAm J Respir Crit Care Med2011184101125113221852542
   PubMed Web of Science ®Google Scholar
• Zia-AmirhosseiniPMinthornEBenincosaLPharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeysJ Pharmacol Exp Ther199929131060106710565825
   PubMed Web of Science ®Google Scholar
• LopezASandersonCGambleJCampbellHYoungIVadasMRecombinant human interleukin 5 is a selective activator of human eosinophil functionJ Exp Med19881672192242826636
   PubMed Web of Science ®Google Scholar
• HartTKCookRZia-AmirhosseiniPPreclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeysJ Allergy Clin Immunol2001108225025711496242
   PubMed Web of Science ®Google Scholar
• KipsJCO’ConnorBJLangleySJEffect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot studyAm J Respir Crit Care Med2003167121655165912649124
   PubMed Web of Science ®Google Scholar
• CastroMZangrilliJWechslerMEReslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomized, placebo-controlled, phase 3 trialsLancet Respir Med20153535536625736990
   PubMed Web of Science ®Google Scholar
• CorrenJWeinsteinSJankaLZangrilliJGarinMPhase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil countsChest2016150479981027018175
   PubMed Web of Science ®Google Scholar
• BjermerLLemiereCMasperoJWeissSZangrilliJGerminaroMReslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 studyChest2016150478979827056586
   PubMed Web of Science ®Google Scholar
• PatrickDLBurkeLBPowersJHPatient-reported outcomes to support medical product labeling claims: FDA perspectiveValue Health200710Suppl 2S125S13717995471
   PubMed Web of Science ®Google Scholar
• CorrenJKavatiAOrtizBPatient-reported outcomes in moderate-to-severe allergic asthmatics treated with omalizumab: a systematic literature review of randomized controlled trialsCurr Med Res Opin2018341658029057669
   PubMed Web of Science ®Google Scholar
• JuniperEFO’ByrnePMGuyattGHDevelopment and validation of a questionnaire to measure asthma controlEur Respir J199914490290710573240
   PubMed Web of Science ®Google Scholar
• JuniperEFSvenssonKMorkACStahlEMeasurement properties and interpretation of three shortened versions of the asthma control questionnaireRespir Med20059955355815823451
   PubMed Web of Science ®Google Scholar
• JaeschkeRSingerJGuyattGHMeasurement of health status. Ascertaining the minimal clinically important differenceControl Clin Trials19891044074152691207
   PubMedGoogle Scholar
• JuniperEFGuyattGHEpsteinRSEvaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trialsThorax199247276831549827
   PubMed Web of Science ®Google Scholar
• RevickiDALeidyNKBrennan-DiemerFIntegrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility IndexChest1998114499810079792568
   PubMed Web of Science ®Google Scholar
• JuniperEFGuyattGHWillanAGriffithLEDetermining a minimal important change in a disease-specific Quality of Life QuestionnaireJ Clin Epidemiol19944781878283197
   PubMed Web of Science ®Google Scholar
• BelEHWenzelSEThompsonPJOral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthmaN Engl J Med2014371131189119725199060
   PubMed Web of Science ®Google Scholar
• LugogoNDomingoCChanezPLong-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb studyClin Ther20163892058207027553751
   PubMed Web of Science ®Google Scholar
• MukherjeeMAleman ParamoFKjarsgaardMWeight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumabAm J Respir Crit Care Med20181971384628915080
   PubMed Web of Science ®Google Scholar
• FroidureAMouthuyJDurhamSRChanezPSibilleYPiletteCAsthma phenotypes and IgE responsesEur Respir J201647130431926677936
   PubMed Web of Science ®Google Scholar
• DomingoCOverlapping effects of new monoclonal antibodies for severe asthmaDrugs201777161769178728948572
   PubMed Web of Science ®Google Scholar
• BrusselleGGerminaroMWeissSZangrilliJReslizumab in patients with inadequately controlled late-onset asthma and elevated blood eosinophilsPulm Pharmacol Ther201743394528159511
   PubMed Web of Science ®Google Scholar
• AlvarezFJBlanco-AparicioMPlazaVDocumento de consenso en asma grave en adultos [Document of consensus on severe asthma in adults]Monografía de Archivos de Bronconeumología2018500158 Spanish
   Google Scholar
• BrusselleGCanvinJWeissSSunSXBuhlRStratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapyERJ Open Res201733 pii:00004-2017
   Google Scholar
• WeinsteinSFGerminaroMBardinPKornSBatemanEDEfficacy of reslizumab with asthma, chronic sinusitis with nasal polyps and elevated blood eosinophilsJ Allergy Clin Immunol2016AB86283
   Google Scholar
• RiveroALiangJAnti-IgE and anti-IL5 biologic therapy in the treatment of nasal polyposis: a systematic review and meta-analysisAnn Otol Rhinol Laryngol20171261173974728918644
   PubMed Web of Science ®Google Scholar
• ChungKFPrecision medicine in asthma: linking phenotypes to targeted treatmentsCurr Opin Pulm Med2017231727902500
   PubMed Web of Science ®Google Scholar
• OrtegaHGLiuMCPavordIDMepolizumab treatment in patients with severe eosinophilic asthmaN Engl J Med2014371131198120725199059
   PubMed Web of Science ®Google Scholar
• FitzGeraldJMBleeckerERNairPBenralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trialLancet2016388100562128214127609406
   PubMed Web of Science ®Google Scholar
• FarneHAWilsonAPowellCBaxLMilanSJAnti-IL5 therapies for asthmaCochrane Database Syst Rev20179CD01083428933516
   PubMed Web of Science ®Google Scholar
• BelEHTen BrinkeA new anti-eosinophil drugs for asthma and COPD: targeting the trait!Chest201715261276128228583618
   PubMed Web of Science ®Google Scholar
• RussellRBrightlingCEAnti-IL-5 for severe asthma: aiming high to achieve successChest2016150476676827719806
   PubMed Web of Science ®Google Scholar